Fig. 5: Olaparib combined with RT increases T cell tumor infiltration.

a Schematic of experimental design with KP1 allografts (Created in BioRender. Ran, X. (2025) https://BioRender.com/e93s595). b Tumor growth curve and Kaplan Meier analysis of KP1 allograft (n = 6 mice for each treatment) treated with olaparib (OLA), RT, or combination (COM) therapy. OLA or vehicle (VEH) was delivered by oral gavage 5 days per week and 8 Gy of RT was delivered on day 2. c Left: Representative of IHC staining for total T cells (CD3⁺) in KP1 tumors upon treatment (n = 3 mice for each treatment, scale bar 250 μm). Right: The quantification of CD3⁺ cells in KP1 tumors. d Schematic of gating strategy for immune profiling. e Left: Representative flow cytometry data for total T cells. Right: Cumulative data for total T cell (CD3⁺CD45⁺, n = 6). f–j Cumulative data for CD4⁺T cell (CD3⁺CD45⁺CD4⁺, n = 6), CD8⁺ T cell (CD3⁺CD45⁺CD8⁺, n = 6), memory CD8⁺ T cell (CD3⁺CD45⁺CD8⁺CD44^highCD62L^low, n = 6), exhausted T cell (CD3⁺CD45⁺TIM-3⁺PD-1⁺, n = 5) and exhausted CD8⁺ T cell (CD3⁺CD45⁺CD8⁺TIM-3⁺PD-1⁺, n = 5). k Cumulative data for PD-L1⁺ cells from KP1 tumors (n = 5). For (b), tumor growth curve data are presented as mean ± SD and statistically analyzed by two-way ANOVA. Kaplan-Meier data are analyzed by log-rank (Mantel-Cox) test. For (c), data are presented as floating bars (min to max) with line at median and statistically analyzed with one-way ANOVA. For (e–k), data are presented as a mean of replicates and statistically analyzed with one-way ANOVA. (p: ****<0.0001 < *** < 0.001 < ** < 0.01 < * < 0.05). All exact p values are listed in the source data. Source data are provided as a Source Data file.